Paving the way for Alzheimer's disease blood-based biomarkers in primary care.

Blood-based biomarkers (BBBMs) for Alzheimer's disease (AD) have the potential to revolutionize the detection and management of cognitive impairment. AD BBBMs are not currently recommended for use in primary care but may soon be as research demonstrates their clinical utility for differential diagnosis and patient management. To prepare for the incorporation of AD BBBMs into primary care, several practical challenges must be addressed. Here, we describe four immediate challenges: (1) preparing primary care providers to order and disclose AD BBBMs, (2) expanding the dementia-capable workforce, (3) ensuring equitable uptake of AD BBBM testing, and (4) securing access to AD treatment. We conclude by discussing future directions and challenges for use of AD BBBMs in primary care, including screening for preclinical AD and dementia detection algorithms. HIGHLIGHTS: Alzheimer's disease (AD) blood-based biomarkers (BBBMs) may be well suited for primary care. Many changes are needed to prepare the workforce and ensure patient access. Paving the way for AD BBBMs in primary care will require a multi-pronged approach.